8 completed, 2 recruiting, 2 unknown, 1 active not recruiting. 15 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 8, Recruiting 2, Unknown 2, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Phase 3 | 2 | Completed 1, Withdrawn 1 |
Follow Toxicity: new trials by email Literature Review of Toxicity trials Research Report on Toxicity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases Online adaptive SBRT, Conventional SBRT - Adaptive Radiotherapy, Stereotactic Body Radiotherapy | Phase 2 | Recruiting | Sun Yat-sen University | 130 | 2024-05-22 | 2025-11-17 |
| Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma Induction Immunotherapy-Toripalimab, Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin, Radiotherapy - Esophageal Squamous Cell Carcinoma, Efficacy | Phase 2 | Completed | Sun Yat-sen University | 170 | 2024-02-15 | 2026-08-03 |
| The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study Short Chain Fatty Acid, Tapioca Flour - Toxicity, Radiation Toxicity | Phase 1 / Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 122 | 2023-12-15 | 2026-10-05 |
| Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE) Apatinib+IE, IE - Effect of Drug, Drug | Phase 2 | Completed | Peking University People's Hospital | 81 | 2022-03-01 | 2024-07-31 |
| Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project ASCAPE-based follow-up strategy - Breast Cancer, Prostate Cancer | Phase 2 | Active not recruiting | Region Örebro County | 500 | 2021-02-01 | 2024-11-19 |
| Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma Apatinib, SHR-1210 - Progression-free Survival, Overall Survival | Phase 2 | Completed | Peking University People's Hospital | 43 | 2018-01-01 | 2020-05-19 |
| Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma pegylated liposomal doxorubicin, pirarubicin - Progression-free Survival, Overall Survival | Phase 2 / Phase 3 | Withdrawn | Peking University People's Hospital | 2017-11-06 | 2020-05-19 | |
| Alpha Lipoic Acid as an Adjuvant Treatment in Acute Phosphide Poisoning Alpha Lipoic Acid (Thioctacid), Placebo (for Alpha Lipoic Acid) - Toxicity | Phase 2 | Unknown | Heba Allah Ali Abd El-Halim Mabrouk | 50 | 2016-05-01 | 2016-05-10 |
| Study of Metronomic Capecitabine and Oxaliplatin Versus XELOX in Egyptian Metastatic Colorectal Cancer Patients metronomic XELOX, Classic XELOX, Blood samples for pharmacological studies - Clinical Response, Toxicity | Phase 2 | Completed | National Cancer Institute, Egypt | 70 | 2016-01-01 | 2020-06-11 |
| The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION) Nab-paclitaxel - Esophageal Cancer, Toxicity | Phase 1 / Phase 2 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 154 | 2014-10-01 | 2017-05-31 |
| Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer Oxaliplatine, Folinic acid, Irinotecan - Pancreatic Metastatic Cancer, Toxicity | Phase 2 | Completed | Institut Cancerologie de l'Ouest | 72 | 2014-07-31 | 2026-04-15 |
| Local Anaesthetics Toxicity and Intralipid® placebo, Intralipid® - Toxicity, Adverse Effects | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 16 | 2011-01-01 | 2016-12-21 |
| Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients Gefitinib, Pemetrexed, Cisplatin or carboplatin - Toxicity, Non-small Cell Lung Cancer | Phase 2 | Unknown | Fudan University | 68 | 2009-12-01 | 2010-09-03 |
| Exclusive Intraoperative Radiation Therapy for Breast Cancer 21 Gy radiation, 18 Gy radiation - Breast Neoplasms, Toxicity | Phase 2 / Phase 3 | Completed | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | 40 | 2009-04-01 | 2017-05-24 |
| MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC) Manganese Superoxide Dismutase Plasmid Liposome, carboplatin, paclitaxel - Esophageal, Toxicity | Phase 1 / Phase 2 | Terminated | Joel Greenberger | 18 | 2005-11-11 | 2021-11-12 |
Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Osteosarcoma (2) · Radiation Injuries (2) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Gastrointestinal Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Prostatic Neoplasms (1) · Sarcoma (1)
Neoplasms (12) · Neoplasms by Site (9) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Gastrointestinal Diseases (4) · Neoplasms by Histologic Type (4) · Gastrointestinal Neoplasms (3) · Lung Diseases (3) · Neoplasms, Connective and Soft Tissue (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3) · Breast Diseases (2) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2)
Capecitabine (2) · Carboplatin (2) · Cisplatin (2) · Oxaliplatin (2) · Radiotherapy (2) · apatinib (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Blood Specimen Collection (1) · Butyric Acid (1) · Fatty Acids, Volatile (1) · Fluorouracil (1) · Gefitinib (1) · Irinotecan (1) · Leucovorin (1)
Peking University People's Hospital (3) · Sun Yat-sen University (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Assistance Publique - Hôpitaux de Paris (1) · Fudan University (1) · Heba Allah Ali Abd El-Halim Mabrouk (1) · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy (1) · Institut Cancerologie de l'Ouest (1) · Joel Greenberger (1) · National Cancer Institute, Egypt (1) · Region Örebro County (1) · UNC Lineberger Comprehensive Cancer Center (1)
China (6) · France (2) · United States (2) · Greece (1) · Italy (1) · Netherlands (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Hui Liu, Professor (2) · Wei Guo, M.D.and Ph.D. (2) · Dan Benhamou (1) · Hanneke WM van Laarhoven, Prof.Dr. (1) · Jianhua Chang, MD,PhD (1) · Joel Greenberger, MD (1) · Marina Guenzi, MD (1) · Paris Kosmidis (1) · Serge Autexier (1) · Shivani Sud, MD (1)
PMID 27404223, PMID 30194205, PMID 32376724, PMID 35446854
2014 (1)